This Program Grant brings together a world-leading team of experts to elucidate mechanisms that protect most people from infection by making antibodies, and their failure caused by genes or infections like influenza or HIV. The team will determine mechanisms that protect most people from making antibodies against normal parts of our body, whose failure causes numerous autoimmune diseases including rheumatoid arthritis. The team will develop ways to engineer better antibodies.
The Elimination Of Hepatitis C As A Global Public Health Threat
Funder
National Health and Medical Research Council
Funding Amount
$7,001,475.00
Summary
In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2 ....In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2030.Read moreRead less
Improving The Health Of People With Problematic Drug Use: Hepatitis C And Drug Dependence
Funder
National Health and Medical Research Council
Funding Amount
$9,060,140.00
Summary
Problematic drug use is the major risk factor to health among Australians aged 15-49 years. The dual harms of drug dependence and hepatitis C virus (HCV) faced by people who use drugs compel improved drug dependence management and HCV prevention and treatment. This Program Grant will improve the lives of people with problematic drug use by investigating health impacts of drug use and evaluating new strategies for managing drug dependence and eliminating HCV among people who use drugs.
Molecular Regulation Of Blood Cell Production And Function
Funder
National Health and Medical Research Council
Funding Amount
$18,330,902.00
Summary
This Program comprises an established team of investigators that have made world-class contributions to the understanding of blood cell formation and function. Research will combine novel multidisciplinary genetic/genomics approaches, expert biochemistry, cell and molecular biological techniques with translational studies in humans to provide new insights into blood cell control and novel avenues for therapies in blood cell diseases such as leukaemia and autoimmune and inflammatory disorders.
Hepatitis C affects a quarter of a million Australians, causing insidious but progressive liver disease which culminates in liver failure or cancer. There is no vaccine and prevention programs have limited effectiveness, but new antiviral therapies now offer high rates of cure. This Program will evaluate strategies to improve the health of those affected and prevent new infections by better understanding of the virus and the body’s immune response, including scarring and liver cancer formation.
Antigen Presentation, Recognition And The Immune Response
Funder
National Health and Medical Research Council
Funding Amount
$15,780,848.00
Summary
This program focuses on understanding the development of immune response to viruses and other infectious agents using a broad array of techniques to dissect the function of various immune cell types and to explore the relationship between structure and function of important cell surface molecules. These studies will improve our ability to design new generation vaccines for combating infectious diseases, controlling cancer, or limiting autoimmune diseases like diabetes.